AGER Protein, Cynomolgus, Recombinant (His)

The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 487.00
500 μg	5 days	$ 1,950.00
1 mg	5 days	$ 3,250.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 487.00

500 μg

5 days

$ 1,950.00

1 mg

5 days

$ 3,250.00

Description

Species	Cynomolgus
Expression System	HEK293
Tag	C-His
Accession Number	A0A2K5TSM4
Synonyms	AGER, RAGE, SCARJ1
Construction	Recombinant Cynomolgus AGER Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gln24-Thr354.[Accession \|A0A2K5TSM4]
Protein Purity	> 95% as determined by Tris-Bis PAGE
Molecular Weight	The protein has a predicted MW of 36.78 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.